Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.

This publication has 17 references indexed in Scilit:

• Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease
  The American Journal of Cardiology, 1995
• Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokalemia, and hypomagnesemia
  American Heart Journal, 1994
• Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor
  The American Journal of Cardiology, 1994
• Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end‐diastolic pressure
  Clinical Cardiology, 1993
• Angiotensin-Converting Enzyme Inhibition Does Not Suppress Plasma Angiotensin II Increase During Exercise in Humans
  Journal of Cardiovascular Pharmacology, 1993
• Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor
  The American Journal of Cardiology, 1993
• Aldosterone and antialdosterone therapy in congestive heart failure
  The American Journal of Cardiology, 1993
• Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension.
  Heart, 1987
• Comparison of Captopril and Enalapril in Patients with Severe Chronic Heart Failure
  New England Journal of Medicine, 1986
• COMBINED SPIRONOLACTONE AND CONVERTING‐ENZYME INHIBITOR THERAPY FOR REFRACTORY HEART FAILURE
  Australian and New Zealand Journal of Medicine, 1986